Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors

This article was originally published in The Gray Sheet

Executive Summary

Abbott will try to leverage its installed U.S. base of 5,000 AxSYM automated analyzers to gain a competitive advantage over Bayer Diagnostics as each firm prepares a 2003 launch of a B-type natriuretic peptide (BNP) test to help diagnose congestive heart failure
Advertisement

Related Content

Biosite BNP Test Reimbursed At $47 In Tentative Payment Determination
Biosite BNP Test Reimbursed At $47 In Tentative Payment Determination
To Cross-Walk Or Gap-Fill? CMS Ponders BNP Test Reimbursement Options
To Cross-Walk Or Gap-Fill? CMS Ponders BNP Test Reimbursement Options
Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Roche NT-proBNP CHF Test Launch Expected By Jan. Pending FDA Approval
Advertisement
UsernamePublicRestriction

Register

MT016950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel